Literature DB >> 18306362

Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria.

Zakari Y Aliyu1, Victor Gordeuk, Vandana Sachdev, Aliyu Babadoko, Aisha I Mamman, Peter Akpanpe, Ester Attah, Yusuf Suleiman, Nurudeen Aliyu, Jamilu Yusuf, Laurel Mendelsohn, Gregory J Kato, Mark T Gladwin.   

Abstract

Pulmonary artery systolic hypertension is common and associated with increased mortality among adult sickle cell disease (SCD) patients in the United States. Although the prevalence of SCD is highest in sub-Saharan Africa, the frequency of pulmonary artery systolic hypertension and the risk factors for the development of pulmonary hypertension have not been reported from Africa. We studied 208 hydroxyurea naïve Nigerian SCD patients at steady state and 94 healthy controls. Pulmonary artery systolic hypertension was defined prospectively as tricuspid regurgitant jet velocity > or =2.5 m/sec. Results were compared with a previously published US prospective SCD cohort. Only 7% of Nigerians compared with 46% of US adults with SCD were >35 years. Tricuspid regurgitant jet velocity was > or =2.5 m/sec in 25% of Nigerian SCD patients. Higher jet velocity was associated with greater serum globulin (P = 0.002), blood urea nitrogen (P = 0.019) and lactate dehydrogenase concentrations (P = 0.026) and with inability to walk >300 m in 6 min (P = 0.042). Compared with the US cohort, Nigerian patients had more hemolysis as indicated by lower hemoglobin and higher lactate dehydrogenase concentrations (P < or = 0.003). Pulmonary hypertension is common among Nigerian SCD patients. The public health implication of this finding is significant considering the potential number of individuals at risk for this complication. Better understanding of the long term outcome of pulmonary hypertension and causes of death in SCD and the institution of preventive measures are major public health challenges for Africa. The inclusion of African sites in sickle cell pulmonary hypertension clinical trials should be encouraged. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18306362      PMCID: PMC3415268          DOI: 10.1002/ajh.21162

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  22 in total

1.  Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography.

Authors:  Miguel A Quiñones; Catherine M Otto; Marcus Stoddard; Alan Waggoner; William A Zoghbi
Journal:  J Am Soc Echocardiogr       Date:  2002-02       Impact factor: 5.251

2.  Ethics. Fair benefits for research in developing countries.

Authors: 
Journal:  Science       Date:  2002-12-13       Impact factor: 47.728

3.  Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study.

Authors:  Roberto de Cleva; Paulo Herman; Vincenzo Pugliese; Bruno Zilberstein; William Abrão Saad; Joaquim Jose Gama Rodrigues; Antonio Atílio Laudanna
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

4.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

5.  Current therapy of sickle cell disease.

Authors:  Zakari Y Aliyu; Ashaunta R Tumblin; Gregory J Kato
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

6.  Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria.

Authors:  Irene Gramaglia; Peter Sobolewski; Diana Meays; Ramiro Contreras; John P Nolan; John A Frangos; Marcos Intaglietta; Henri C van der Heyde
Journal:  Nat Med       Date:  2006-11-12       Impact factor: 53.440

7.  Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.

Authors:  R W Hagar; C R Morris; E P Vichinsky
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

8.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

Review 9.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

Review 10.  HIV-Related pulmonary hypertension: analytic review of 131 cases.

Authors:  N J Mehta; I A Khan; R N Mehta; D A Sepkowitz
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

View more
  35 in total

Review 1.  Pulmonary complications of sickle cell disease.

Authors:  Andrew C Miller; Mark T Gladwin
Journal:  Am J Respir Crit Care Med       Date:  2012-03-23       Impact factor: 21.405

2.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

3.  An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.

Authors:  Abdelsattar M Omar; Osheiza Abdulmalik; Mohini S Ghatge; Yosra A Muhammad; Steven D Paredes; Moustafa E El-Araby; Martin K Safo
Journal:  Biomolecules       Date:  2020-11-02

4.  NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa.

Authors:  Zakari Y Aliyu; Aisha Suleiman; Ester Attah; Aisha I Mamman; Aliyu Babadoko; Mehdi Nouraie; Laurel Mendelsohn; Gregory J Kato; Victor R Gordeuk; Mark T Gladwin
Journal:  Br J Haematol       Date:  2010-04-16       Impact factor: 6.998

Review 5.  Pleiotropic effects of intravascular haemolysis on vascular homeostasis.

Authors:  Gregory J Kato; James G Taylor
Journal:  Br J Haematol       Date:  2009-12-01       Impact factor: 6.998

6.  Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population.

Authors:  Marco Marziali; Antonella Isgrò; Javid Gaziev; Guido Lucarelli
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-26       Impact factor: 2.576

Review 7.  Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Authors:  Santosh L Saraf; Robert E Molokie; Mehdi Nouraie; Craig A Sable; Lori Luchtman-Jones; Gregory J Ensing; Andrew D Campbell; Sohail R Rana; Xiao M Niu; Roberto F Machado; Mark T Gladwin; Victor R Gordeuk
Journal:  Paediatr Respir Rev       Date:  2013-11-15       Impact factor: 2.726

Review 8.  The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae).

Authors:  I E Cock
Journal:  Inflammopharmacology       Date:  2015-07-31       Impact factor: 4.473

Review 9.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

10.  Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low-resource setting: evidence from the SPRING trial.

Authors:  Halima Bello-Manga; Aisha A Galadanci; Shehu Abdullahi; Shehi Ali; Binta Jibir; Safiya Gambo; Lawal Haliru; Lori C Jordan; Muktar H Aliyu; Mark Rodeghier; Adetola A Kassim; Michael R DeBaun; Najibah A Galadanci
Journal:  Br J Haematol       Date:  2020-05-16       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.